Castle Biosciences (CSTL) EBIT (2018 - 2025)
Historic EBIT for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$6.8 million.
- Castle Biosciences' EBIT fell 23396.34% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 326541.43%. This contributed to the annual value of $8.7 million for FY2024, which is 11275.43% up from last year.
- Castle Biosciences' EBIT amounted to -$6.8 million in Q3 2025, which was down 23396.34% from -$4.3 million recorded in Q2 2025.
- Over the past 5 years, Castle Biosciences' EBIT peaked at $5.1 million during Q3 2024, and registered a low of -$31.5 million during Q1 2023.
- In the last 5 years, Castle Biosciences' EBIT had a median value of -$8.8 million in 2021 and averaged -$11.1 million.
- Its EBIT has fluctuated over the past 5 years, first plummeted by 126589.15% in 2021, then soared by 17158.01% in 2024.
- Castle Biosciences' EBIT (Quarter) stood at -$15.2 million in 2021, then plummeted by 50.5% to -$22.8 million in 2022, then surged by 75.22% to -$5.7 million in 2023, then soared by 171.58% to $4.0 million in 2024, then tumbled by 268.0% to -$6.8 million in 2025.
- Its last three reported values are -$6.8 million in Q3 2025, -$4.3 million for Q2 2025, and -$27.9 million during Q1 2025.